HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
A new study is shining a light on a potential way to make treatments work better for one of the deadliest forms of cancer. Researchers at Ohio University have identified a protein that could be a ...
The Commissioner’s National Priority Voucher pilot program enabled rolling review, enhanced FDA interaction, and a rapid 44-day decision, alongside breakthrough therapy and priority review ...
The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...
Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results